Trademark: 97772656
Word
GOFYXII
Status
Registered
Status Code
700
Status Date
Tuesday, October 24, 2023
Serial Number
97772656
Registration Number
7202080
Registration Date
Tuesday, October 24, 2023
Mark Type
4000
Filing Date
Monday, January 30, 2023
Published for Opposition
Tuesday, August 8, 2023

Trademark Owner History
CSL Behring GmbH - Original Registrant

Classifications
5 Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Trademark Events
Oct 24, 2023
Notice Of Registration Confirmation Emailed
Oct 24, 2023
Registered-Principal Register
Aug 8, 2023
Official Gazette Publication Confirmation E-Mailed
Aug 8, 2023
Published For Opposition
Jul 19, 2023
Notification Of Notice Of Publication E-Mailed
Jun 30, 2023
Approved For Pub - Principal Register
Jun 30, 2023
Teas/Email Correspondence Entered
Jun 30, 2023
Correspondence Received In Law Office
May 26, 2023
Teas Response To Office Action Received
May 23, 2023
Notification Of Non-Final Action E-Mailed
May 23, 2023
Non-Final Action E-Mailed
May 23, 2023
Non-Final Action Written
May 16, 2023
Assigned To Examiner
May 15, 2023
Petition To Director - Make Special - Granted
May 15, 2023
Assigned To Petition Staff
May 8, 2023
Teas Petition To Director-Make Special-Received
Feb 16, 2023
New Application Office Supplied Data Entered
Feb 2, 2023
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24